In hepatocellular carcinoma, the copresence of IGF2BP3 and its target CD44 is correlated with advanced tumor stage/grade and metastasis (Wachter et al., 2012; Hu et al., 2014), while in Ewing sarcoma patients, contemporary high expression of IGF2BP3 and low expression of its counteracting partner ABCF1 is correlated with a particularly poor outcome (Mancarella et al., 2018b). This evidence concerns the gene IGF2BP3 and Ewing sarcoma.